Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25829653 | 0.82 | TRPA1 (0.38) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18544267 | 0.78 | TRPA1 (0.38) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21050753 | 0.78 | TRPA1 (0.38) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL26694677 | 0.69 | TRPA1 (0.32) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21563189 | 0.66 | CSNK2A1 (0.36) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27882381 | 0.66 | TRPA1 (0.39) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29517451 | 0.66 | TRPA1 (0.39) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21598410 | 0.65 | CCR4 (0.37) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2240307 | 0.65 | TRPA1 (0.54) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12336177 | 0.65 | KCNA5 (0.51) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364254-B2 | Compounds for use in antibacterial applications | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | CFTR, MRPL21, CLPP | TRPA1 420/4885CYP1A2 4380/4885CYP3A4 3048/4885 |
| US-10364254-B2 | Compounds for use in antibacterial applications | MRPL21, CFTR, NRDC | TRPA1 727/4885CYP1A2 3905/4885CYP3A4 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.